1. A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study. Issue 10374 (4th February 2023) Authors: Swen, Jesse J; van der Wouden, Cathelijne H; Manson, Lisanne EN; Abdullah-Koolmees, Heshu; Blagec, Kathrin; Blagus, Tanja; Böhringer, Stefan; Cambon-Thomsen, Anne; Cecchin, Erika; Cheung, Ka-Chun; Deneer, Vera HM; Dupui, Mathilde; Ingelman-Sundberg, Magnus; Jonsson, Siv; Joefield-Roka, Candace; J... Journal: Lancet Issue: Volume 401:Issue 10374(2023) Page Start: 347 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A p53/miR-30a/ZEB2 axis controls triple negative breast cancer aggressiveness. Issue 12 (December 2018) Authors: di Gennaro, Alessandra; Damiano, Valentina; Brisotto, Giulia; Armellin, Michela; Perin, Tiziana; Zucchetto, Antonella; Guardascione, Michela; Spaink, Herman; Doglioni, Claudio; Snaar-Jagalska, B.; Santarosa, Manuela; Maestro, Roberta Journal: Cell death and differentiation Issue: Volume 25:Issue 12(2018) Page Start: 2165 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. CYP2D6 and CYP2C8 pharmacogenetics and pharmacological interactions to predict imatinib plasmatic exposure in GIST patients. Issue 3 (19th October 2022) Authors: Dalle Fratte, Chiara; Gagno, Sara; Roncato, Rossana; Polesel, Jerry; Zanchetta, Martina; Buzzo, Mauro; Posocco, Bianca; De Mattia, Elena; Borsatti, Rachele; Puglisi, Fabio; Foltran, Luisa; Guardascione, Michela; Buonadonna, Angela; Cecchin, Erika; Toffoli, Giuseppe Journal: British journal of clinical pharmacology Issue: Volume 89:Issue 3(2023) Page Start: 1089 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Epigenetic silencing of miR‐200c in breast cancer is associated with aggressiveness and is modulated by ZEB1. Issue 2 (1st November 2016) Authors: Damiano, Valentina; Brisotto, Giulia; Borgna, Silvia; di Gennaro, Alessandra; Armellin, Michela; Perin, Tiziana; Guardascione, Michela; Maestro, Roberta; Santarosa, Manuela Journal: Genes, chromosomes & cancer Issue: Volume 56:Issue 2(2017:Feb.) Page Start: 147 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. MGMT promoter methylation status in brain metastases from colorectal cancer and corresponding primary tumors. (April 2015) Authors: Maglio, Giovanna De; Casagrande, Mariaelena; Guardascione, Michela; Fontanella, Caterina; Lutrino, Stefania Eufemia; Rihawi, Karim; Pisa, Federica Edith; Tuniz, Francesco; Fasola, Gianpiero; Pizzolitto, Stefano; Aprile, Giuseppe Journal: Future oncology Issue: Volume 11:Number 8(2015) Page Start: 1201 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Pharmacological strategies to prevent SARS-CoV-2 infection and treat the early phases of COVID-19. (March 2021) Authors: Scarabel, Lucia; Guardascione, Michela; Dal Bo, Michele; Toffoli, Giuseppe Journal: International journal of infectious diseases Issue: Volume 104(2021) Page Start: 441 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. The Genotype for DPYD Risk Variants in Patients With Colorectal Cancer and the Related Toxicity Management Costs in Clinical Practice. Issue 4 (22nd November 2018) Authors: Toffoli, Giuseppe; Innocenti, Federico; Polesel, Jerry; De Mattia, Elena; Sartor, Franca; Dalle Fratte, Chiara; Ecca, Fabrizio; Dreussi, Eva; Palazzari, Elisa; Guardascione, Michela; Buonadonna, Angela; Foltran, Luisa; Garziera, Marica; Bignucolo, Alessia; Nobili, Stefania; Mini, Enrico; Favarett... Journal: Clinical pharmacology & therapeutics Issue: Volume 105:Issue 4(2019) Page Start: 994 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗